<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Prim CareJ Family Med Prim CareJFMPCJournal of Family Medicine and" exact="Primary" post="Care2249-48632278-7135Wolters Kluwer - MedknowIndia pmcid: 7113931JFMPC-9-531 doi: 10.4103/jfmpc.jfmpc_943_19 :"/>
 <result pre="Article Emerging resistance to directly-acting antiviral therapy in treatment of" exact="chronic" post="Hepatitis C infection—A brief review of literature BhatiaMohit1GuptaEkta2[1], Department"/>
 <result pre="Emerging resistance to directly-acting antiviral therapy in treatment of chronic" exact="Hepatitis" post="C infection—A brief review of literature BhatiaMohit1GuptaEkta2[1], Department of"/>
 <result pre="Rishikesh, Uttarakhand, India[2], Department of Virology, Institute of Liver and" exact="Biliary" post="Sciences, New Delhi, India Address for correspondence: Dr. Ekta"/>
 <result pre="Dr. Ekta Gupta, Department of Virology, Institute of Liver and" exact="Biliary" post="Sciences, New Delhi, India. E-mail: ektagaurisha@gmail.com collection: 2020-2epub: 2020-2-292531538received:"/>
 <result pre="the new creations are licensed under the identical terms. Abstract" exact="Hepatitis" post="caused by Hepatitis C virus (HCV) is a major"/>
 <result pre="are licensed under the identical terms. Abstract Hepatitis caused by" exact="Hepatitis" post="C virus (HCV) is a major cause of chronic"/>
 <result pre="by Hepatitis C virus (HCV) is a major cause of" exact="chronic" post="liver disease. HCV is transmitted by injection drug use,"/>
 <result pre="Hepatitis C virus (HCV) is a major cause of chronic" exact="liver disease." post="HCV is transmitted by injection drug use, blood transfusion,"/>
 <result pre="as a global health problem because of the progression to" exact="cirrhosis" post="and hepatocellular carcinoma. Globally, about 170 million people are"/>
 <result pre="global health problem because of the progression to cirrhosis and" exact="hepatocellular carcinoma." post="Globally, about 170 million people are infected with HCV."/>
 <result pre="discovery of this virus in 1989, the clinical management of" exact="chronic hepatitis" post="C infection has undergone a paradigm shift from alpha"/>
 <result pre="of this virus in 1989, the clinical management of chronic" exact="hepatitis" post="C infection has undergone a paradigm shift from alpha"/>
 <result pre="virus in 1989, the clinical management of chronic hepatitis C" exact="infection" post="has undergone a paradigm shift from alpha interferon to"/>
 <result pre="vitro DAA resistance testing in clinical practice. Directly acting antiviral" exact="Hepatitis" post="C virus resistance Introduction Hepatitis C virus (HCV) is"/>
 <result pre="clinical practice. Directly acting antiviral Hepatitis C virus resistance Introduction" exact="Hepatitis" post="C virus (HCV) is a single-stranded RNA virus belonging"/>
 <result pre="belonging to Hepacivirus genus of the Flaviviridae family. It causes" exact="hepatitis" post="C which is a major chronic liver disease. Hepatitis"/>
 <result pre="Flaviviridae family. It causes hepatitis C which is a major" exact="chronic" post="liver disease. Hepatitis C is transmitted by injection drug"/>
 <result pre="family. It causes hepatitis C which is a major chronic" exact="liver disease." post="Hepatitis C is transmitted by injection drug use, blood"/>
 <result pre="causes hepatitis C which is a major chronic liver disease." exact="Hepatitis" post="C is transmitted by injection drug use, blood transfusion,"/>
 <result pre="as a global health problem because of the progression to" exact="cirrhosis" post="and hepatocellular carcinoma. Globally, about 170 million people are"/>
 <result pre="global health problem because of the progression to cirrhosis and" exact="hepatocellular carcinoma." post="Globally, about 170 million people are infected with HCV."/>
 <result pre="discovery of this virus in 1989, the clinical management of" exact="chronic hepatitis" post="C infection has undergone a paradigm shift from alpha"/>
 <result pre="of this virus in 1989, the clinical management of chronic" exact="hepatitis" post="C infection has undergone a paradigm shift from alpha"/>
 <result pre="virus in 1989, the clinical management of chronic hepatitis C" exact="infection" post="has undergone a paradigm shift from alpha interferon to"/>
 <result pre="vitro DAA resistance testing in clinical practice. Structural organization of" exact="Hepatitis" post="C virus HCV is an enveloped virus harboring a"/>
 <result pre="HCV polyprotein is cleaved co- and posttranslationally by cellular and" exact="viral" post="proteases into ten different products which are broadly classified"/>
 <result pre="Proten Type Functions HCV core protein Structural Makes up the" exact="viral" post="nucleocapsid. Affects host cell functions like gene transcription, lipid"/>
 <result pre="signaling pathways Directly or indirectly involved in hepatocarcinogenesis and steatosis" exact="hepatitis" post="Envelope proteins E1 and E2 Structural Play an important"/>
 <result pre="viroporins. Forms ion channels that play an essential role in" exact="virus infection." post="Essential for virus particle assembly and release of infectious"/>
 <result pre="ion channels that play an essential role in virus infection." exact="Essential" post="for virus particle assembly and release of infectious virions"/>
 <result pre="virus infection. Essential for virus particle assembly and release of" exact="infectious" post="virions in a genotype specific manner NS2 protein Nonstructural"/>
 <result pre="infectious virions in a genotype specific manner NS2 protein Nonstructural" exact="Essential" post="for completion of the viral replication cycle in vitro"/>
 <result pre="specific manner NS2 protein Nonstructural Essential for completion of the" exact="viral" post="replication cycle in vitro and in vivo. NS3 protein"/>
 <result pre="Nonstructural Plays an important role in the recruitment of other" exact="viral" post="proteins. NS5A protein Nonstructural Plays an important role in"/>
 <result pre="viral proteins. NS5A protein Nonstructural Plays an important role in" exact="viral" post="replication and modulation of cell signaling pathways and interferon"/>
 <result pre="the synthesis of new RNA genome. Natural history of HCV" exact="infection" post="Infection with HCV can present either as acute or"/>
 <result pre="synthesis of new RNA genome. Natural history of HCV infection" exact="Infection" post="with HCV can present either as acute or chronic"/>
 <result pre="of HCV infection Infection with HCV can present either as" exact="acute" post="or chronic hepatitis. Acute hepatitis is usually asymptomatic and"/>
 <result pre="HCV infection Infection with HCV can present either as acute" exact="or chronic" post="hepatitis. Acute hepatitis is usually asymptomatic and rarely leads"/>
 <result pre="infection Infection with HCV can present either as acute or" exact="chronic hepatitis." post="Acute hepatitis is usually asymptomatic and rarely leads to"/>
 <result pre="with HCV can present either as acute or chronic hepatitis." exact="Acute" post="hepatitis is usually asymptomatic and rarely leads to hepatic"/>
 <result pre="HCV can present either as acute or chronic hepatitis. Acute" exact="hepatitis" post="is usually asymptomatic and rarely leads to hepatic failure."/>
 <result pre="is usually asymptomatic and rarely leads to hepatic failure. Symptomatic" exact="acute" post="HCV infection has a mild clinical course with less"/>
 <result pre="asymptomatic and rarely leads to hepatic failure. Symptomatic acute HCV" exact="infection" post="has a mild clinical course with less than one"/>
 <result pre="(&amp;lt;25%) of patients presenting with jaundice. About 60–80% patients with" exact="acute" post="infection develop chronic infection.[23] The rate of spontaneous viral"/>
 <result pre="of patients presenting with jaundice. About 60–80% patients with acute" exact="infection" post="develop chronic infection.[23] The rate of spontaneous viral clearance"/>
 <result pre="presenting with jaundice. About 60–80% patients with acute infection develop" exact="chronic" post="infection.[23] The rate of spontaneous viral clearance in patients"/>
 <result pre="with acute infection develop chronic infection.[23] The rate of spontaneous" exact="viral" post="clearance in patients with chronic HCV is very low."/>
 <result pre="infection.[23] The rate of spontaneous viral clearance in patients with" exact="chronic" post="HCV is very low. Approximately, one fifth (20–30%) of"/>
 <result pre="is very low. Approximately, one fifth (20–30%) of patients with" exact="chronic" post="HCV infection develop cirrhosis over a period of 10–30"/>
 <result pre="low. Approximately, one fifth (20–30%) of patients with chronic HCV" exact="infection" post="develop cirrhosis over a period of 10–30 years.[24] 1–4%"/>
 <result pre="one fifth (20–30%) of patients with chronic HCV infection develop" exact="cirrhosis" post="over a period of 10–30 years.[24] 1–4% of cirrhotic"/>
 <result pre="a period of 10–30 years.[24] 1–4% of cirrhotic patients develop" exact="hepatocellular carcinoma" post="per year.[25] There are several factors which may determine"/>
 <result pre="period of 10–30 years.[24] 1–4% of cirrhotic patients develop hepatocellular" exact="carcinoma" post="per year.[25] There are several factors which may determine"/>
 <result pre="There are several factors which may determine the rapidity of" exact="disease" post="progression which include: HCV acquisition at an advanced age"/>
 <result pre="male sex, HIV co-infection, high body mass index, presence of" exact="hepatic steatosis," post="and alcohol consumption. Patients with cirrhosis can decompensate with"/>
 <result pre="index, presence of hepatic steatosis, and alcohol consumption. Patients with" exact="cirrhosis" post="can decompensate with complications like portal hypertension, ascites, spontaneous"/>
 <result pre="alcohol consumption. Patients with cirrhosis can decompensate with complications like" exact="portal hypertension," post="ascites, spontaneous bacterial peritonitis, esophageal varices, hepatic encephalopathy and"/>
 <result pre="cirrhosis can decompensate with complications like portal hypertension, ascites, spontaneous" exact="bacterial" post="peritonitis, esophageal varices, hepatic encephalopathy and hepatic coma, and"/>
 <result pre="decompensate with complications like portal hypertension, ascites, spontaneous bacterial peritonitis," exact="esophageal varices," post="hepatic encephalopathy and hepatic coma, and hepatorenal syndrome leading"/>
 <result pre="like portal hypertension, ascites, spontaneous bacterial peritonitis, esophageal varices, hepatic" exact="encephalopathy" post="and hepatic coma, and hepatorenal syndrome leading to renal"/>
 <result pre="hypertension, ascites, spontaneous bacterial peritonitis, esophageal varices, hepatic encephalopathy and" exact="hepatic coma," post="and hepatorenal syndrome leading to renal failure. Chronic infection"/>
 <result pre="bacterial peritonitis, esophageal varices, hepatic encephalopathy and hepatic coma, and" exact="hepatorenal syndrome" post="leading to renal failure. Chronic infection can also be"/>
 <result pre="peritonitis, esophageal varices, hepatic encephalopathy and hepatic coma, and hepatorenal" exact="syndrome" post="leading to renal failure. Chronic infection can also be"/>
 <result pre="hepatic encephalopathy and hepatic coma, and hepatorenal syndrome leading to" exact="renal failure." post="Chronic infection can also be associated with extra-hepatic manifestations"/>
 <result pre="and hepatic coma, and hepatorenal syndrome leading to renal failure." exact="Chronic" post="infection can also be associated with extra-hepatic manifestations such"/>
 <result pre="hepatic coma, and hepatorenal syndrome leading to renal failure. Chronic" exact="infection" post="can also be associated with extra-hepatic manifestations such as"/>
 <result pre="can also be associated with extra-hepatic manifestations such as cryoglobulinemia," exact="porphyria" post="cutanea tarda, arthralgia, membranoproliferative glomerulonephritis, Sjogren's syndrome, Raynaud's syndrome,"/>
 <result pre="with extra-hepatic manifestations such as cryoglobulinemia, porphyria cutanea tarda, arthralgia," exact="membranoproliferative glomerulonephritis," post="Sjogren's syndrome, Raynaud's syndrome, idiopathic thrombocytopenic purpura, and non-Hodgkin's"/>
 <result pre="manifestations such as cryoglobulinemia, porphyria cutanea tarda, arthralgia, membranoproliferative glomerulonephritis," exact="Sjogren's syndrome," post="Raynaud's syndrome, idiopathic thrombocytopenic purpura, and non-Hodgkin's lymphoma.[26] Problem"/>
 <result pre="as cryoglobulinemia, porphyria cutanea tarda, arthralgia, membranoproliferative glomerulonephritis, Sjogren's syndrome," exact="Raynaud's syndrome," post="idiopathic thrombocytopenic purpura, and non-Hodgkin's lymphoma.[26] Problem statement The"/>
 <result pre="porphyria cutanea tarda, arthralgia, membranoproliferative glomerulonephritis, Sjogren's syndrome, Raynaud's syndrome," exact="idiopathic thrombocytopenic purpura," post="and non-Hodgkin's lymphoma.[26] Problem statement The global prevalence of"/>
 <result pre="cutanea tarda, arthralgia, membranoproliferative glomerulonephritis, Sjogren's syndrome, Raynaud's syndrome, idiopathic" exact="thrombocytopenic purpura," post="and non-Hodgkin's lymphoma.[26] Problem statement The global prevalence of"/>
 <result pre="membranoproliferative glomerulonephritis, Sjogren's syndrome, Raynaud's syndrome, idiopathic thrombocytopenic purpura, and" exact="non-Hodgkin's" post="lymphoma.[26] Problem statement The global prevalence of HCV infection"/>
 <result pre="and non-Hodgkin's lymphoma.[26] Problem statement The global prevalence of HCV" exact="infection" post="is estimated at 2–3%.[27282930] The prevalence of HCV is"/>
 <result pre="North America, Australia, Japan, and Northern and Western Europe report" exact="lower" post="prevalence of HCV infection, with no country showing a"/>
 <result pre="2%. Owing to the paucity of large-scale prevalence studies on" exact="hepatitis" post="C in the general population of India, the reported"/>
 <result pre="is prevalent in Egypt, genotype 4c is highly prevalent in" exact="Central" post="Africa. Genotype 5 has mainly been reported from South"/>
 <result pre="clinical relevance and has been recently found in patients from" exact="Central" post="Africa and Thailand.[3040414243444546] Treatment of chronic Hepatitis C—An evolutionary"/>
 <result pre="found in patients from Central Africa and Thailand.[3040414243444546] Treatment of" exact="chronic" post="Hepatitis C—An evolutionary perspective The treatment of chronic hepatitis"/>
 <result pre="in patients from Central Africa and Thailand.[3040414243444546] Treatment of chronic" exact="Hepatitis" post="C—An evolutionary perspective The treatment of chronic hepatitis C"/>
 <result pre="Treatment of chronic Hepatitis C—An evolutionary perspective The treatment of" exact="chronic hepatitis" post="C virus infection has been rapidly evolving since early"/>
 <result pre="of chronic Hepatitis C—An evolutionary perspective The treatment of chronic" exact="hepatitis" post="C virus infection has been rapidly evolving since early"/>
 <result pre="Hepatitis C—An evolutionary perspective The treatment of chronic hepatitis C" exact="virus infection" post="has been rapidly evolving since early 1990s with interferon-alfa."/>
 <result pre="C—An evolutionary perspective The treatment of chronic hepatitis C virus" exact="infection" post="has been rapidly evolving since early 1990s with interferon-alfa."/>
 <result pre="43%. In 2002, pegylated interferon-alfa was approved for treatment of" exact="chronic hepatitis" post="C. Combined with ribavirin, permanent response rates of 52%"/>
 <result pre="In 2002, pegylated interferon-alfa was approved for treatment of chronic" exact="hepatitis" post="C. Combined with ribavirin, permanent response rates of 52%"/>
 <result pre="pegylated interferon-alfa was approved for treatment of chronic hepatitis C." exact="Combined" post="with ribavirin, permanent response rates of 52% were obtained"/>
 <result pre="protease inhibitors were introduced namely boceprevir and telaprevir.[47] Treatment of" exact="chronic" post="HCV with PEG-IFN and ribavirin and, more recently, with"/>
 <result pre="associated with interferon therapy, there are various contraindications like pregnancy," exact="breast" post="feeding, and allergic reactions. The recent development of a"/>
 <result pre="assembly has ushered a new era in the treatment of" exact="hepatitis" post="C.[50] The DAAs are molecules that target specific nonstructural"/>
 <result pre="that target specific nonstructural proteins of HCV thereby interfering with" exact="viral" post="replication and infection. There are four classes of DAAs,"/>
 <result pre="leads to the generation of large number of genetically distinct" exact="viral" post="variants called &quot;quasispecies&quot;.[5556] Some quasispecies bear polymorphisms in drug-targeted"/>
 <result pre="Some quasispecies bear polymorphisms in drug-targeted genes resulting in reduced" exact="susceptibility to" post="DAAs.[57] The prevalence of intrinsically resistant variants within a"/>
 <result pre="replicative fitness. Typically, a dominant variant is detectable within the" exact="viral" post="quasispecies along with less-fit variants that are present at"/>
 <result pre="viral quasispecies along with less-fit variants that are present at" exact="lower" post="frequencies. The presence of minor populations of resistance-associated variants"/>
 <result pre="the resistant viruses to emerge as the dominant species. However," exact="viral" post="variants harbouring substitutions associated with resistance to directing-acting antivirals"/>
 <result pre="antivirals (DAAs) are detectable prior to antiviral therapy in few" exact="chronic" post="HCV infected patients and are referred to as baseline"/>
 <result pre="by their ability to maintain high replication competence in the" exact="absence of" post="continued drug pressure. This allows these viral variants to"/>
 <result pre="in the absence of continued drug pressure. This allows these" exact="viral" post="variants to remain as the dominant viral quasispecies for"/>
 <result pre="This allows these viral variants to remain as the dominant" exact="viral" post="quasispecies for prolonged periods relative to NS3 protease or"/>
 <result pre="of achieving SVR.[64] Drug-specific RASs that are found at a" exact="lower" post="frequency may not convey sufficient resistance to reduce SVR"/>
 <result pre="to treatment regimen and patient factors such as presence of" exact="cirrhosis" post="and fold change decrease in potency conferred by the"/>
 <result pre="testing can be considered for genotype 1a-infected, treatment-experienced patients without" exact="cirrhosis" post="being considered for ledipasvir/sofosbuvir. If clinically importanta resistance is"/>
 <result pre="testing can be considered for genotype 1a-infected, treatment-experienced patients with" exact="cirrhosis" post="being considered for ledipasvir/sofosbuvir. If clinically importanta resistance is"/>
 <result pre="RAS testing is recommended for genotype 3-infected, treatment-naive patients with" exact="cirrhosis" post="and treatment-experienced patients (with or without cirrhosis) being considered"/>
 <result pre="RAS testing is recommended for genotype 3-infected, treatment-experienced patients without" exact="cirrhosis" post="being considered for 12 weeks of daclatasvir plus sofosbuvir."/>
 <result pre="RAS testing is recommended for genotype 3-infected, treatment-naive patients with" exact="cirrhosis" post="being considered for 24 weeks of daclatasvir plus sofosbuvir."/>
 <result pre="patients with genotype 1, 2, 3, 4, 5, or 6" exact="infection" post="being considered for glecaprevir/pibrentasvir for 8, 12, or 16"/>
 <result pre="not recommended for genotype 1a- or 1b-infected, treatment-naive patients without" exact="cirrhosis" post="and with a viral load &amp;lt;6 million IU/mL being"/>
 <result pre="1a- or 1b-infected, treatment-naive patients without cirrhosis and with a" exact="viral" post="load &amp;lt;6 million IU/mL being considered for an 8-week"/>
 <result pre="for patients with genotype 1, 2, 4, 5, or 6" exact="infection" post="and considered for 12 weeks of sofosbuvir/velpatasvir therapy. I,"/>
 <result pre="patients with genotype 1, 2, 3, 4, 5, or 6" exact="infection" post="and considered for 12 weeks of sofosbuvir/velpatasvir/voxilaprevir therapy. I,"/>
 <result pre="of replication levels for variants and wild-type constructs in the" exact="absence of" post="drug allows for the estimation of fitness. Directly acting"/>
 <result pre="for the estimation of fitness. Directly acting antiviral therapy and" exact="primary" post="healthcare The treatment and monitoring requirements of regimens containing"/>
 <result pre="requirements of regimens containing Direct Acting Antivirals (DAAs) are much" exact="lower" post="than those containing interferon and ribavirin. Also, DAAs have"/>
 <result pre="environments should be feasible.[65] To achieve the World Health Organization" exact="Hepatitis" post="C virus elimination targets, it is essential to increase"/>
 <result pre="access to treatment. Hence, DAA treatment can be provided in" exact="primary" post="healthcare services in order to improve accessibility and retention"/>
 <result pre="settings where compared to published studies and real-world clinics in" exact="secondary" post="care. However, stronger study designs are needed to confirm"/>
 <result pre="and some healthcare facilities are also providing antiviral treatment for" exact="chronic" post="Hepatitis B infection/disease. The National Viral Hepatitis Control Programme"/>
 <result pre="some healthcare facilities are also providing antiviral treatment for chronic" exact="Hepatitis" post="B infection/disease. The National Viral Hepatitis Control Programme (NVHCP)"/>
 <result pre="providing antiviral treatment for chronic Hepatitis B infection/disease. The National" exact="Viral" post="Hepatitis Control Programme (NVHCP) under National Health Mission (NHM),"/>
 <result pre="antiviral treatment for chronic Hepatitis B infection/disease. The National Viral" exact="Hepatitis" post="Control Programme (NVHCP) under National Health Mission (NHM), Government"/>
 <result pre="and guidance on testing and management of different types of" exact="viral hepatitis" post="(namely A, B, C, D, and E viruses, respectively)."/>
 <result pre="guidance on testing and management of different types of viral" exact="hepatitis" post="(namely A, B, C, D, and E viruses, respectively)."/>
 <result pre="objectives of NVHCP are as follows[67]: Enhance community awareness on" exact="hepatitis" post="and lay stress on preventive measures among general population,"/>
 <result pre="groups and in hotspots. Provide early diagnosis and management of" exact="viral hepatitis" post="at all levels of healthcare. Develop standard diagnostic and"/>
 <result pre="and in hotspots. Provide early diagnosis and management of viral" exact="hepatitis" post="at all levels of healthcare. Develop standard diagnostic and"/>
 <result pre="healthcare. Develop standard diagnostic and treatment protocols for management of" exact="viral hepatitis" post="and its complications. Strengthen the existing infrastructure facilities, build"/>
 <result pre="Develop standard diagnostic and treatment protocols for management of viral" exact="hepatitis" post="and its complications. Strengthen the existing infrastructure facilities, build"/>
 <result pre="resources, where required, for providing comprehensive services for management of" exact="viral hepatitis" post="and its complications in all districts of the country."/>
 <result pre="where required, for providing comprehensive services for management of viral" exact="hepatitis" post="and its complications in all districts of the country."/>
 <result pre="existing National programmes towards awareness, prevention, diagnosis, and treatment for" exact="viral hepatitis." post="Develop a web-based &quot;Viral Hepatitis Information and Management System&quot;"/>
 <result pre="diagnosis, and treatment for viral hepatitis. Develop a web-based &quot;Viral" exact="Hepatitis" post="Information and Management System&quot; to maintain a registry of"/>
 <result pre="Management System&quot; to maintain a registry of persons affected with" exact="viral hepatitis" post="and its sequelae. Owing to the recent developments pertaining"/>
 <result pre="System&quot; to maintain a registry of persons affected with viral" exact="hepatitis" post="and its sequelae. Owing to the recent developments pertaining"/>
 <result pre="Owing to the recent developments pertaining to the management of" exact="chronic" post="HCV infection with DAA therapy at primary healthcare level,"/>
 <result pre="the recent developments pertaining to the management of chronic HCV" exact="infection" post="with DAA therapy at primary healthcare level, it is"/>
 <result pre="the management of chronic HCV infection with DAA therapy at" exact="primary" post="healthcare level, it is imperative for physicians to be"/>
 <result pre="in order to avoid their misuse. Conclusion Management of HCV" exact="infection" post="is a challenge for both hepatologists and virologists alike."/>
 <result pre="patients on DAA therapy who fail to attain a sustained" exact="viral" post="response. Keeping in mind the emerging concept of management"/>
 <result pre="response. Keeping in mind the emerging concept of management of" exact="chronic" post="HCV infections at the primary healthcare level, physicians should"/>
 <result pre="in mind the emerging concept of management of chronic HCV" exact="infections" post="at the primary healthcare level, physicians should be made"/>
 <result pre="emerging concept of management of chronic HCV infections at the" exact="primary" post="healthcare level, physicians should be made aware of the"/>
 <result pre="the HCV NS5B polymerase: New hope for the treatment of" exact="hepatitis" post="C infectionsCurr Opin Investig Drugs2004583850 3AshfaqUAJavedTRehmanSNawazZRiazuddinSAn overview of HCV"/>
 <result pre="responsesVirol J2011816121477382 4BukhJPurcellRHMillerRHSequence analysis of the core gene of 14" exact="hepatitis" post="C virus genotypesProc Natl Acad Sci USA1994918239438058787 5SantoliniEMigliaccioGLa MonicaNBiosynthesis"/>
 <result pre="Acad Sci USA1994918239438058787 5SantoliniEMigliaccioGLa MonicaNBiosynthesis and biochemical properties of the" exact="hepatitis" post="C virus core proteinJ Virol1994683631418189501 6HopeRGMurphyDJMcLauchlanJThe domains required to"/>
 <result pre="proteinJ Virol1994683631418189501 6HopeRGMurphyDJMcLauchlanJThe domains required to direct core proteins of" exact="hepatitis" post="C virus and GB virus-B to lipid droplets share"/>
 <result pre="features with plant oleosin proteinsJ Biol Chem200227742617011706032 7LeratHHondaMBeardMRLoeschKSunJYangYet al.Steatosis and" exact="liver cancer" post="in transgenic mice expressing the structural and nonstructural proteins"/>
 <result pre="with plant oleosin proteinsJ Biol Chem200227742617011706032 7LeratHHondaMBeardMRLoeschKSunJYangYet al.Steatosis and liver" exact="cancer" post="in transgenic mice expressing the structural and nonstructural proteins"/>
 <result pre="in transgenic mice expressing the structural and nonstructural proteins of" exact="hepatitis" post="C virusGastroenterology20021223526511832450 8TellinghuisenTLRiceCMInteraction between hepatitis C virus proteins and"/>
 <result pre="structural and nonstructural proteins of hepatitis C virusGastroenterology20021223526511832450 8TellinghuisenTLRiceCMInteraction between" exact="hepatitis" post="C virus proteins and host cell factorsCurr Opin Microbiol200254192712160863"/>
 <result pre="host cell factorsCurr Opin Microbiol200254192712160863 9DrummerHEMaerzAPoumbouriosPCell surface expression of functional" exact="hepatitis" post="C virus E1 and E2 glycoproteinsFEBS Lett20035463859012832074 10GoffardACallensNBartoschBWychowskiCCossetFLMontpellierCet al.Role"/>
 <result pre="Lett20035463859012832074 10GoffardACallensNBartoschBWychowskiCCossetFLMontpellierCet al.Role of N-linked glycans in the functions of" exact="hepatitis" post="C virus envelope glycoproteinsJ Virol2005798400915956584 11GriffinSDBealesLPClarkeDSWorsfoldOEvansSDJaegerJet al.The p7 protein"/>
 <result pre="C virus envelope glycoproteinsJ Virol2005798400915956584 11GriffinSDBealesLPClarkeDSWorsfoldOEvansSDJaegerJet al.The p7 protein of" exact="hepatitis" post="C virus forms an ion channel that is blocked"/>
 <result pre="virus p7 protein is crucial for assembly and release of" exact="infectious" post="virionsPLoS Pathog20073e10317658949 13KhromykhAAWestawayEG1997Subgenomic replicons of the flavivirus Kunjin1497505 14PietschmannTKaulAKoutsoudakisGShavinskayaAKallisSSteinmannEet"/>
 <result pre="replicons of the flavivirus Kunjin1497505 14PietschmannTKaulAKoutsoudakisGShavinskayaAKallisSSteinmannEet al.Construction and characterization of" exact="infectious" post="intragenotypic and intergenotypic hepatitis C virus chimerasProc Natl Acad"/>
 <result pre="Kunjin1497505 14PietschmannTKaulAKoutsoudakisGShavinskayaAKallisSSteinmannEet al.Construction and characterization of infectious intragenotypic and intergenotypic" exact="hepatitis" post="C virus chimerasProc Natl Acad Sci USA200610374081316651538 15GallinariPBrennanDNardiCBrunettiMTomeiLSteinkuhlerCet al.Multiple"/>
 <result pre="15GallinariPBrennanDNardiCBrunettiMTomeiLSteinkuhlerCet al.Multiple enzymatic activities associated with recombinant NS3 protein of" exact="hepatitis" post="C virusJ Virol1998726758699658124 16WolkBSansonnoDKrausslichHGDammaccoFRiceCMBlumHEet al.Subcellular localization, stability, and trans-cleavage"/>
 <result pre="Virol1998726758699658124 16WolkBSansonnoDKrausslichHGDammaccoFRiceCMBlumHEet al.Subcellular localization, stability, and trans-cleavage competence of the" exact="hepatitis" post="C virus NS3-NS4A complex expressed in tetracycline-regulated cell linesJ"/>
 <result pre="expressed in tetracycline-regulated cell linesJ Virol200074229330410666260 17AsabeSITanjiYSatohSKanekoTKimuraKShimotohnoKThe N-terminal region of" exact="hepatitis" post="C virus-encoded NS5A is important for NS4A-dependent phosphorylationJ Virol19977179068985418"/>
 <result pre="C virus-encoded NS5A is important for NS4A-dependent phosphorylationJ Virol19977179068985418 18LinCWuJWHsiaoKSuMSThe" exact="hepatitis" post="C virus NS4A protein: Interactions with the NS4B and"/>
 <result pre="Interactions with the NS4B and NS5A proteinsJ Virol1997716465719261364 19HugleTFehrmannFBieckEKoharaMKrausslichHGRiceCMet al.The" exact="hepatitis" post="C virus nonstructural protein 4B is an integral endoplasmic"/>
 <result pre="protein 4B is an integral endoplasmic reticulum membrane proteinVirology2001284708111352669 20MacdonaldACrowderKStreetAMcCormickCHarrisMThe" exact="hepatitis" post="C virus NS5A protein binds to members of the"/>
 <result pre="kinases and regulates kinase activityJ Gen Virol200485721914993658 21ReedKEXuJRiceCMPhosphorylation of the" exact="hepatitis" post="C virus NS5A protein in vitro and in vivo:"/>
 <result pre="22BehrensSETomeiLDe FrancescoRIdentification and properties of the RNA-dependent RNA polymerase of" exact="hepatitis" post="C virusEmbo J1996151228598194 23HoofnagleJHCourse and outcome of hepatitis CHepatology2002365"/>
 <result pre="polymerase of hepatitis C virusEmbo J1996151228598194 23HoofnagleJHCourse and outcome of" exact="hepatitis" post="CHepatology2002365 Suppl 1S21912407573 24ThomasDLSeeLBNatural history of hepatitis CClin Liver"/>
 <result pre="and outcome of hepatitis CHepatology2002365 Suppl 1S21912407573 24ThomasDLSeeLBNatural history of" exact="hepatitis" post="CClin Liver Dis200593839816023972 25FattovichGStroffoliniTZagniIDonatoFHepatocellular carcinoma in cirrhosis: Incidence and"/>
 <result pre="Suppl 1S21912407573 24ThomasDLSeeLBNatural history of hepatitis CClin Liver Dis200593839816023972 25FattovichGStroffoliniTZagniIDonatoFHepatocellular" exact="carcinoma" post="in cirrhosis: Incidence and risk factorsGastroenterology20041275 Suppl 1S355015508101 26LiangTJRehermannBSeeLBHoofnagleJHPathogenesis,"/>
 <result pre="factorsGastroenterology20041275 Suppl 1S355015508101 26LiangTJRehermannBSeeLBHoofnagleJHPathogenesis, natural history, treatment, and prevention of" exact="hepatitis" post="CAnn Intern Med200013229630510681285 27LavanchyDThe global burden of hepatitis CLiver"/>
 <result pre="prevention of hepatitis CAnn Intern Med200013229630510681285 27LavanchyDThe global burden of" exact="hepatitis" post="CLiver Int200929Suppl 17481 28collab: Global Burden Of Hepatitis C"/>
 <result pre="burden of hepatitis CLiver Int200929Suppl 17481 28collab: Global Burden Of" exact="Hepatitis" post="C Working GroupGlobal burden of disease (GBD) for hepatitis"/>
 <result pre="28collab: Global Burden Of Hepatitis C Working GroupGlobal burden of" exact="disease" post="(GBD) for hepatitis CJ Clin Pharmacol20044420914681338 29LavanchyDEvolving epidemiology of"/>
 <result pre="Of Hepatitis C Working GroupGlobal burden of disease (GBD) for" exact="hepatitis" post="CJ Clin Pharmacol20044420914681338 29LavanchyDEvolving epidemiology of hepatitis C virusClin"/>
 <result pre="disease (GBD) for hepatitis CJ Clin Pharmacol20044420914681338 29LavanchyDEvolving epidemiology of" exact="hepatitis" post="C virusClin Microbiol Infect2011171071521091831 30Hepatitis C--global prevalence (update)Wkly Epidemiol"/>
 <result pre="Infect2011171071521091831 30Hepatitis C--global prevalence (update)Wkly Epidemiol Rec199974425710645164 31NerrienetEPouillotRLachenalGNjouomRMfoupouendounJBilongCet al.Hepatitis C" exact="virus infection" post="in cameroon: A cohort-effectJ Med Virol2005762081415834878 32GuerraJGarenneMMohamedMKFontanetAHCV burden of"/>
 <result pre="30Hepatitis C--global prevalence (update)Wkly Epidemiol Rec199974425710645164 31NerrienetEPouillotRLachenalGNjouomRMfoupouendounJBilongCet al.Hepatitis C virus" exact="infection" post="in cameroon: A cohort-effectJ Med Virol2005762081415834878 32GuerraJGarenneMMohamedMKFontanetAHCV burden of"/>
 <result pre="infection in cameroon: A cohort-effectJ Med Virol2005762081415834878 32GuerraJGarenneMMohamedMKFontanetAHCV burden of" exact="infection" post="in Egypt: Results from a nationwide surveyJ Viral Hepat201219560722762140"/>
 <result pre="burden of infection in Egypt: Results from a nationwide surveyJ" exact="Viral" post="Hepat201219560722762140 33MukhopadhyayaAHepatitis C in IndiaJ Biosci2008334657319208972 34SimmondsPBukhJCombetCDeléageGEnomotoNFeinstoneSet al.Consensus proposals"/>
 <result pre="34SimmondsPBukhJCombetCDeléageGEnomotoNFeinstoneSet al.Consensus proposals for a unified system of nomenclature of" exact="hepatitis" post="C virus genotypesHepatology2005429627316149085 35GottweinJMBukhJCutting the gordian knot-development and biological"/>
 <result pre="virus genotypesHepatology2005429627316149085 35GottweinJMBukhJCutting the gordian knot-development and biological relevance of" exact="hepatitis" post="C virus cell culture systemsAdv Virus Res2008715113318585527 36SmithDBBukhJKuikenCMuerhoffASRiceCMStapletonJTet al.Expanded"/>
 <result pre="virus cell culture systemsAdv Virus Res2008715113318585527 36SmithDBBukhJKuikenCMuerhoffASRiceCMStapletonJTet al.Expanded classification of" exact="hepatitis" post="C virus into 7 genotypes and 67 subtypes: Updated"/>
 <result pre="and time of infectionJ Clin Virol200842156918353714 38TalloTNorderHTefanovaVKrispinTSchmidtJIlmojaMet al.Genetic characterization of" exact="hepatitis" post="C virus strains in Estonia: Fluctuations in the predominating"/>
 <result pre="predominating subtype with timeJ Med Virol2007793748217311333 39KatsoulidouASypsaVTassopoulosNCBoletisJKarafoulidouAKetikoglouIet al.Molecular epidemiology of" exact="hepatitis" post="C virus (HCV) in Greece: Temporal trends in HCV"/>
 <result pre="HCV genotype-specific incidence and molecular characterization of genotype 4 isolatesJ" exact="Viral" post="Hepat200613192716364078 40SievertWAltraifIRazaviHAAbdoAAhmedEAAlomairAet al.Asystematic review of hepatitis C virus epidemiology"/>
 <result pre="of genotype 4 isolatesJ Viral Hepat200613192716364078 40SievertWAltraifIRazaviHAAbdoAAhmedEAAlomairAet al.Asystematic review of" exact="hepatitis" post="C virus epidemiology in Asia, Australia and EgyptLiver Int201131Suppl"/>
 <result pre="Asia, Australia and EgyptLiver Int201131Suppl 2618021651703 41ChaoDTAbeKNguyenMHSystematic review: Epidemiology of" exact="hepatitis" post="C genotype 6 and its managementAliment Pharmacol Ther2011342869621623850 42NguyenMHKeeffeEBPrevalence"/>
 <result pre="6 and its managementAliment Pharmacol Ther2011342869621623850 42NguyenMHKeeffeEBPrevalence and treatment of" exact="hepatitis" post="C virus genotypes 4, 5, and 6Clin Gastroenterol Hepatol20053S9710116234071"/>
 <result pre="4, 5, and 6Clin Gastroenterol Hepatol20053S9710116234071 43MaussSBergerFVogelMPfeiffer-VornkahlHAlshuthURockstrohJKet al.Treatment results of" exact="chronic hepatitis" post="C genotype 5 and 6 infections in GermanyZ Gastroenterol201250441422581697"/>
 <result pre="5, and 6Clin Gastroenterol Hepatol20053S9710116234071 43MaussSBergerFVogelMPfeiffer-VornkahlHAlshuthURockstrohJKet al.Treatment results of chronic" exact="hepatitis" post="C genotype 5 and 6 infections in GermanyZ Gastroenterol201250441422581697"/>
 <result pre="al.Treatment results of chronic hepatitis C genotype 5 and 6" exact="infections" post="in GermanyZ Gastroenterol201250441422581697 44BostanNMahmoodTAn overview about hepatitis C: A"/>
 <result pre="5 and 6 infections in GermanyZ Gastroenterol201250441422581697 44BostanNMahmoodTAn overview about" exact="hepatitis" post="C: A devastating virusCrit Rev Microbiol2010369113320345213 45BunchorntavakulCChavalitdhamrongDTanwandeeTHepatitis C genotype"/>
 <result pre="and response-guided therapy proposalWorld J Hepatol2013549650424073301 46CornbergMRazaviHAAlbertiABernasconiEButiMCooperCet al.Asystematic review of" exact="hepatitis" post="C virus epidemiology in Europe, Canada and IsraelLiver Int201131Suppl"/>
 <result pre="epidemiology in Europe, Canada and IsraelLiver Int201131Suppl 2306021651702 47Porter L." exact="Hepatitis" post="C: The Evolution of Treatment [Internet]. Lucinda Porter, RN"/>
 <result pre="25Available from: http://www.lucindaporterrn.com/hepatitis-c-the-evolution-of-treatment/ 48GhanyMGNelsonDRStraderDBDavidLTLeonardBSAn update on treatment of genotype 1" exact="chronic hepatitis" post="C virus infection: 2011 practice guidelines by the American"/>
 <result pre="from: http://www.lucindaporterrn.com/hepatitis-c-the-evolution-of-treatment/ 48GhanyMGNelsonDRStraderDBDavidLTLeonardBSAn update on treatment of genotype 1 chronic" exact="hepatitis" post="C virus infection: 2011 practice guidelines by the American"/>
 <result pre="chronic hepatitis C virus infection: 2011 practice guidelines by the" exact="American" post="Association for the Study of Liver DiseasesHepatology20115414334421898493 49JacobsonIMPawlotskyJMAfdhalNHDusheikoGMFornsXJensenDMet al.A"/>
 <result pre="the use of Boceprevir and Telaprevir for the treatment of" exact="hepatitis" post="CJ Viral Hepatitis201219Suppl 2126 50MannsMCornbergMSofosbuvir: The final nail in"/>
 <result pre="of Boceprevir and Telaprevir for the treatment of hepatitis CJ" exact="Viral" post="Hepatitis201219Suppl 2126 50MannsMCornbergMSofosbuvir: The final nail in the coffin"/>
 <result pre="Hepatitis201219Suppl 2126 50MannsMCornbergMSofosbuvir: The final nail in the coffin for" exact="hepatitis" post="CLancet Infectious Diseases201313378923499157 51PoordadFDieterichDTreating hepatitis C: Current standard of"/>
 <result pre="50MannsMCornbergMSofosbuvir: The final nail in the coffin for hepatitis CLancet" exact="Infectious" post="Diseases201313378923499157 51PoordadFDieterichDTreating hepatitis C: Current standard of care and"/>
 <result pre="nail in the coffin for hepatitis CLancet Infectious Diseases201313378923499157 51PoordadFDieterichDTreating" exact="hepatitis" post="C: Current standard of care and emerging direct-acting antiviral"/>
 <result pre="C: Current standard of care and emerging direct-acting antiviral agentsJ" exact="Viral" post="Hepat20121944922676357 52LontokEHarringtonPHoweAKiefferTLennerstrandJLenzOet al.Hepatitis C virus drug resistance-associated substitutions: State"/>
 <result pre="virus drugs in developmentGastroenterology2012142134022537441 54PockrosPJDirect-acting antivirals for the treatment of" exact="hepatitis" post="C virus infectionLast accessed on 2018 Jun 25UpToDate 55PawlotskyJMGermanidisGFrainaisPOBouvierMSoulierAPellerinMet"/>
 <result pre="infectionLast accessed on 2018 Jun 25UpToDate 55PawlotskyJMGermanidisGFrainaisPOBouvierMSoulierAPellerinMet al.Evolution of the" exact="hepatitis" post="C virus second envelope protein hypervariable region in chronically"/>
 <result pre="infected patients receiving α interferon therapyJ Virol1999736490910400744 56NeumannAULamNPDahariHGretchDRWileyTELaydenTJet al.Hepatitis C" exact="viral" post="dynamicsin vivo and the antiviral efficacy of interferon-α therapyScience199828210379756471"/>
 <result pre="Hepatol20096383519575020 58PawlotskyJMTreatment failure and resistance with direct-acting antiviral drugs against" exact="hepatitis" post="C virusHepatology20115317425121374691 59VermehrenJSarrazinCThe role of resistance in HCV treatmentBest"/>
 <result pre="al.In vitro activity and resistance profile of dasabuvir, a nonnucleoside" exact="hepatitis" post="C virus polymerase inhibitorAntimicrob Agents Chemother20155915051125534735 61collab: Hcvguidelines.org. (2018)."/>
 <result pre="C virus polymerase inhibitorAntimicrob Agents Chemother20155915051125534735 61collab: Hcvguidelines.org. (2018). HCV" exact="Resistance" post="Primer | HCV Guidance. [online]Last accessed 2018 Jun 29Available"/>
 <result pre="from: https://www.hcvguidelines.org/evaluate/resistance 62SvarovskaiaESDvory-SobolHParkinNHebnerCGontcharovaVMartinRet al.Infrequent development of resistance in genotype 1-6" exact="hepatitis" post="C virus-infected subjects treated with sofosbuvir in phase 2"/>
 <result pre="regimensGastroenterology2016151708627080301 65RadleyARobinsonEAspinallEJAngusKTanLDillonJSA systematic review and meta-analysis of community and primary-care-based" exact="hepatitis" post="C testing and treatment services that employ direct acting"/>
 <result pre="Res201919765doi: 10.1186/s12913-019-4635-731660966 66WadeAJDoyleJSGaneEStedmanCDraperBIserDet al.Community-based provision of direct-acting antiviral therapy for" exact="hepatitis" post="C: Study protocol and challenges of a randomized controlled"/>
</results>
